Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Mehmet Asim Bilen"'
Autor:
Wayne Harris, Bradley C. Carthon, Shreyas S. Joshi, Julie M. Shabto, Deepak Ravindranathan, Jacqueline T. Brown, Omer Kucuk, Sarah Caulfield, Kenneth Ogan, Dylan J. Martini, Viraj A. Master, Haydn T. Kissick, Lauren Yantorni, Emilie Elise Hitron, Mehmet Asim Bilen, Yuan Liu, Greta Russler, Bassel Nazha
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
BackgroundThe modified Glasgow Prognostic Score (mGPS) is a composite biomarker that uses albumin and C reactive protein (CRP). There are multiple immune checkpoint inhibitor (ICI)-based combinations approved for metastatic renal cell carcinoma (mRCC
Autor:
Christina Wu, R. Donald Harvey, Colleen Lewis, Bassel F. El-Rayes, Mehmet Akce, Viraj A. Master, Meredith R Kline, Olatunji B. Alese, Bradley C. Carthon, Yuan Liu, David H. Lawson, Haydn T. Kissick, Walid L. Shaib, Dylan J. Martini, Taofeek K. Owonikoko, Conor E. Steuer, Julie M. Shabto, Ragini R. Kudchadkar, Suresh S. Ramalingam, Mehmet Asim Bilen, Hannah Collins, Rathi N. Pillai
Publikováno v:
Invest New Drugs
Background Given the increasing number of available immunotherapeutic agents, more patients are presenting after failing immunotherapy in need of new treatment options. In this study, we investigated the clinical outcomes of patients treated with seq
Autor:
Saby George, Christine Chevreau, DD Chism, Gabrial G. Malouf, Xiaoping Su, Maria I. Carlo, Toni K. Choueiri, A Coulomb-L'hermine, M-D. Tabone, Dominick Bossé, Nizar M. Tannir, Martin H. Voss, Judith Landman-Parker, Philippe Barthélémy, Alice Boilève, Asim Amin, Stéphane Oudard, Mehmet Asim Bilen, Delphine Borchiellini
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-10 (2018)
Journal for Immunotherapy of Cancer, BMJ Publishing Group 2018, 6 (1), ⟨10.1186/s40425-018-0482-z⟩
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-10 (2018)
Journal for Immunotherapy of Cancer, BMJ Publishing Group 2018, 6 (1), ⟨10.1186/s40425-018-0482-z⟩
Background Microphthalmia Transcription Factor (MITF)family translocation renal cell carcinoma (tRCC) is a rare RCC subtype harboring TFE3/TFEB translocations. The prognosis in the metastatic (m) setting is poor. Programmed death ligand-1 expression
33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)
Autor:
Sekwon Jang, Scott S. Tykodi, Igor Puzanov, Fiore Cattaruzza, Ute Hoch, Alexander Spira, Ewa Kalinka Warzocha, Karl D. Lewis, Jonathan Zalevsky, Gregory A. Daniels, Mike Hurwitz, Brendan D. Curti, Dariusz Sawka, Alison L. Hannah, Mary Tagliaferri, Chantale Bernatchez, Wendy L. Clemens, Christie Fanton, Mario Sznol, Cara Haymaker, James Larkin, Adi Diab, Michael H. Wong, Michele Maio, Sandra Aung, Mehmet Asim Bilen, Giovanni Grignani, Daniel Cho, Salah Eddine Bentebibel, Ahsan Naqi Rizwan, Michael Imperiale, Ernesto Iaccucci, Paul Lorigan
Publikováno v:
Journal for ImmunoTherapy of Cancer. 6
Publikováno v:
Expert opinion on investigational drugs. 27(2)
Although significant advances have been made in the treatment of advanced renal cell carcinoma (RCC), patients still develop resistance to standard therapies and require the administration of subsequent lines of treatment. New therapeutic approaches
Autor:
Mehmet Asim Bilen, Rivka R. Colen, Anisha B. Patel, Filip Janku, Ajay Sheshadri, Joud Hajjar, Apostolia Maria Tsimberidou, David S. Hong, Padmanee Sharma, Vivek Subbiah, Tito R. Mendoza, Siqing Fu, Sarina Anne Piha-Paul, Anas Alshawa, Aung Naing, Kenneth R. Hess, Funda Meric-Bernstam, Bettzy Stephen, Maria E. Suarez-Almazor, Selvi Thirumurthi, Jing Gong, Takeo Fujii
Publikováno v:
Investigational new drugs. 36(4)
Background Immunotherapy is emerging as the cornerstone for treatment of patients with advanced cancer, but significant toxicity (immune-related adverse events [irAEs]) associated with unbridled T cell activity remains a concern. Patients and methods
Autor:
Mehmet Asim Bilen, Paul G. Corn, Ana Aparicio, Sue Hwa Lin, Christopher J. Logothetis, Kenneth R. Hess, Amado Zurita-Saavedra, John C. Araujo, Jessica T. Stover, Shi Ming Tu, Jeri Kim, Sumit K. Subudhi
Publikováno v:
Cancer chemotherapy and pharmacology. 80(3)
We evaluated the patterns of progression and determined clinical predictors of survival in patients with castration-resistant prostate cancer (CRPCa) who received sipuleucel-T. We retrospectively analyzed 56 consecutive patients with asymptomatic or
Autor:
Aung Naing, Funda Meric-Bernstam, Naifa L. Busaidy, Javier Munoz, Filip Janku, Mouhammed Amir Habra, Amy Patel, Mehmet Asim Bilen, Kenneth R. Hess, David S. Hong, Gerald S. Falchook, Jennifer J. Wheler
Publikováno v:
Cancer chemotherapy and pharmacology. 78(1)
Tyrosine kinase inhibitor (TKI)-induced thyroid dysfunction has been identified as an important but manageable adverse effect of targeted therapy. Several studies have suggested that patients who develop hypothyroidism respond better to TKIs, but thi
Autor:
Mehmet Asim Bilen, Giselle Dutcher
Publikováno v:
Vaccines, Vol 6, Iss 3, p 55 (2018)
Vaccines
Vaccines
The field of genitourinary malignancies has been a showcase for therapeutic cancer vaccine success since the application of intravesicular Bacillus Calmette-Guerin (BCG) for bladder cancer in the 1970s and enjoyed a renaissance in 2010 with the US Fo
Autor:
Jennifer J. Wheler, David S. Hong, Michael S. Ewer, Razelle Kurzrock, Kenneth R. Hess, Siqing Fu, Gerald S. Falchook, Jean-Bernard Durand, Lacey McQuinn, Mehmet Asim Bilen, Rabih Said, Aung Naing
Publikováno v:
Investigational new drugs. 32(4)
Background The purposes of this study were to establish a novel blood pressure (BP) scoring method and to correlate it with clinical response in advanced cancer patients treated with anti-vascular endothelial growth factor (VEGF) therapies. Methods W